{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:26:07Z","timestamp":1793352367758,"version":"4.5.0"},"reference-count":39,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GSK","award":["GSK study 214106"],"award-info":[{"award-number":["GSK study 214106"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2024,3,4]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the real-world impact of intravenous belimumab treatment among patients with SLE using rheumatoid arthritis-derived disease activity measures and SLE-related laboratory values.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective cohort study used US electronic medical record data from the United Rheumatology Normalised Integrated Community Evidence (UR-NICE) database. Adult patients with SLE who initiated intravenous belimumab between 1 January 2012 and 3 December 2019 (index), had 12 months of pre-index and 24 months of post-index clinical activity, and had \u22656 infusions of belimumab during the 24 months post-index were included. The primary outcome measure was time to first improvement of minimally important difference (MID) for Routine Assessment of Patient Index Data 3 (RAPID3), Patient Pain Index (PPI), swollen joint count, tender joint count (TJC), complement C3 and C4 and anti-double-stranded DNA antibodies during the on-treatment follow-up period of up to 24 months. The secondary outcome measure evaluated the trajectories of these outcome measures for up to 24 months of belimumab treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 495 patients included, between 21.0% and 52.1% had \u22651 record for each of the disease activity measures or laboratory values in the pre-index and post-index periods and were included in analyses for that measure. The proportion of patients achieving MID for each measure increased rapidly within 3 months, with continued gradual improvement throughout the remaining on-treatment period, up to 24 months. After 6 months, 52.3% and 55.3% of patients had achieved MID in RAPID3 and PPI, respectively. Outcome measure trajectories indicated improved disease activity with belimumab treatment, particularly in RAPID3, TJC and laboratory values.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this real-world effectiveness study, belimumab therapy for SLE resulted in clinically meaningful improvements in rheumatoid arthritis-derived disease activity measures within 3 months of treatment, with patients who remained on belimumab therapy experiencing improvement even up to 24 months of observation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2023-001111","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:40Z","timestamp":1712188840000},"page":"e001111","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count"],"prefix":"10.1136","volume":"11","author":[{"given":"Guillaume","family":"Germain","sequence":"first","affiliation":[{"name":"Groupe d'analyse, Lt\u00e9e, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0952-8883","authenticated-orcid":false,"given":"Karen","family":"Worley","sequence":"additional","affiliation":[{"name":"Value, Evidence & Outcomes, GSK Collegeville, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D","family":"MacKnight","sequence":"additional","affiliation":[{"name":"Groupe d'analyse, Lt\u00e9e, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Rubin","sequence":"additional","affiliation":[{"name":"US Medical Affairs and Immuno-inflammation, GSK, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6413-2537","authenticated-orcid":false,"given":"Christopher F","family":"Bell","sequence":"additional","affiliation":[{"name":"US Value, Evidence and Outcomes, GSK, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[{"name":"Groupe d'analyse, Lt\u00e9e, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Urosevic","sequence":"additional","affiliation":[{"name":"Groupe d'analyse, Lt\u00e9e, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Sheng Duh","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Concoff","sequence":"additional","affiliation":[{"name":"Hauppauge, NY and Exagen, United Rheumatology, Vista, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"2025091515052156000_11.1.e001111.1","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025091515052156000_11.1.e001111.2","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0702-6","article-title":"Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research","volume":"17","author":"Mikdashi","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025091515052156000_11.1.e001111.3","first-page":"S","article-title":"Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care","volume":"32","author":"Castrej\u00f3n","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2025091515052156000_11.1.e001111.4","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu2021oa"},{"key":"2025091515052156000_11.1.e001111.5","first-page":"261","article-title":"A 5-year retrospective, observational study assessing rheumatoid arthritis disease outcome measures to characterize systemic lupus erythematosus burden in the USA","volume":"10","author":"Bell","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025091515052156000_11.1.e001111.6","first-page":"S14","article-title":"Measures of rheumatoid arthritis disease activity: patient (PtGA) and provider (PrGA) global assessment of disease activity, disease activity score (DAS) and disease activity score with 28-joint counts (DAS28), simplified disease activity index (SDAI), clinical disease activity index (CDAI), patient activity score (PAS) and patient activity score-II (PASII), routine assessment of patient index data (RAPID), rheumatoid arthritis disease activity index (RADAI) and rheumatoid arthritis disease activity Index-5 (RADAI-5), chronic arthritis systemic index (CASI), patient-based disease activity score with ESR (PDAS1) and patient-based disease activity score without ESR (PDAS2), and mean overall index for rheumatoid arthritis (MOI-RA)","volume":"63 Suppl 11","author":"Anderson","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025091515052156000_11.1.e001111.7","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1177\/0961203318758503","article-title":"Psychometric properties of MDHAQ\/RAPID3 in patients with systemic lupus erythematosus","volume":"27","author":"Annapureddy","year":"2018","journal-title":"Lupus"},{"key":"2025091515052156000_11.1.e001111.8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000235","article-title":"Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis","volume":"2","author":"Castrej\u00f3n","year":"2016","journal-title":"RMD Open"},{"key":"2025091515052156000_11.1.e001111.9","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3182936b98"},{"key":"2025091515052156000_11.1.e001111.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101091"},{"key":"2025091515052156000_11.1.e001111.11","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2827-4"},{"key":"2025091515052156000_11.1.e001111.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3256-7"},{"key":"2025091515052156000_11.1.e001111.13","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000277"},{"key":"2025091515052156000_11.1.e001111.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2921-2"},{"key":"2025091515052156000_11.1.e001111.15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.semarthrit.2017.03.022","article-title":"Joint involvement in systemic lupus erythematosus: from pathogenesis to clinical assessment","volume":"47","author":"Ceccarelli","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025091515052156000_11.1.e001111.16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0961203319828527","article-title":"Usefulness of composite indices in the assessment of joint involvement in systemic lupus erythematosus patients: correlation with ultrasonographic score","volume":"28","author":"Ceccarelli","year":"2019","journal-title":"Lupus"},{"key":"2025091515052156000_11.1.e001111.17","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/0961203320979039","article-title":"Joint involvement influences quality of life in systemic lupus erythematosus patients","volume":"30","author":"Natalucci","year":"2021","journal-title":"Lupus"},{"key":"2025091515052156000_11.1.e001111.18","unstructured":"GSK . Belimumab (Benlysta). Highlights of prescribing information. Available: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Benlysta\/pdf\/BENLYSTA-PI-MG-IFU.PDF [Accessed 07 May 2023]."},{"key":"2025091515052156000_11.1.e001111.19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40744-020-00243-2","article-title":"Real-world effectiveness of Belimumab in the treatment of systemic lupus erythematosus: pooled analysis of multi-country data from the observe studies","volume":"7","author":"Collins","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025091515052156000_11.1.e001111.20","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 years of Belimumab experience: what have we learnt","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"2025091515052156000_11.1.e001111.21","unstructured":"Specialty networks. n.d. Available: https:\/\/specialtynetworks.com\/rheumatology\/"},{"key":"2025091515052156000_11.1.e001111.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-018-1055-z","article-title":"Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review","volume":"16","author":"Ousmen","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"2025091515052156000_11.1.e001111.23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/acr.24221","article-title":"Measures of adult systemic lupus erythematosus: disease activity and damage","volume":"72 Suppl 10","author":"Arora","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025091515052156000_11.1.e001111.24","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11020340","article-title":"Patient-reported outcomes in systemic lupus erythematosus. Can lupus patients take the driver\u2019s seat in their disease monitoring?","volume":"11","author":"Parodis","year":"2022","journal-title":"J Clin Med"},{"key":"2025091515052156000_11.1.e001111.25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40744-022-00454-9","article-title":"Real-world effectiveness of Belimumab in systemic lupus erythematosus: a systematic literature review","volume":"9","author":"Huang","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025091515052156000_11.1.e001111.26","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.41253","article-title":"Early disease and low baseline damage as predictors of response to Belimumab in patients with systemic lupus erythematosus in a real-life setting","volume":"72","author":"Gatto","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025091515052156000_11.1.e001111.27","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13040691","article-title":"Early and late response and glucocorticoid-sparing effect of Belimumab in patients with systemic lupus erythematosus with joint and skin manifestations: results from the Belimumab in real life setting study\u2014joint and skin (Berliss-JS)","volume":"13","author":"Zen","year":"2023","journal-title":"J Pers Med"},{"key":"2025091515052156000_11.1.e001111.28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074044","article-title":"Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on Belimumab treatment: a real-life, Multicentre observational study","volume":"13","author":"Nikoloudaki","year":"2022","journal-title":"Front Immunol"},{"key":"2025091515052156000_11.1.e001111.29","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120886"},{"key":"2025091515052156000_11.1.e001111.30","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000118","article-title":"Response to Belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the observe study in the USA","volume":"3","author":"Collins","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2025091515052156000_11.1.e001111.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2025091515052156000_11.1.e001111.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2025091515052156000_11.1.e001111.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205139"},{"key":"2025091515052156000_11.1.e001111.34","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025091515052156000_11.1.e001111.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"2025091515052156000_11.1.e001111.36","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu332oa"},{"key":"2025091515052156000_11.1.e001111.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080182"},{"key":"2025091515052156000_11.1.e001111.38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/acr.25030","article-title":"Association of hurried communication and low patient self\u2010efficacy with persistent nonadherence to lupus medications","volume":"75","author":"Barr","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025091515052156000_11.1.e001111.39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00296-018-4016-2","article-title":"Physician\u2013patient communication in rheumatology: a systematic review","volume":"38","author":"Georgopoulou","year":"2018","journal-title":"Rheumatol Int"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2023-001111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:05:33Z","timestamp":1757973933000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2023-001111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,4,3]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/lupus-2023-001111"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2023-001111","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}